The biology of ependymomas and emerging novel therapies

Ependymomas are rare central nervous system tumours that can arise in the brain's supratentorial region or posterior fossa, or in the spinal cord. In 1924, Percival Bailey published the first comprehensive study of ependymomas. Since then, and especially over the past 10 years, our understanding of ependymomas has grown exponentially. In this Review, we discuss the evolution in knowledge regarding ependymoma subgroups and the resultant clinical implications. We also discuss key oncogenic and tumour suppressor signalling pathways that regulate tumour growth, the role of epigenetic dysregulation in the biology of ependymomas, and the various biological features of ependymoma tumorigenesis, including cell immortalization, stem cell-like properties, the tumour microenvironment and metastasis. We further review the limitations of current therapies such as relapse, radiation-induced cognitive deficits and chemotherapy resistance. Finally, we highlight next-generation therapies that are actively being explored, including tyrosine kinase inhibitors, telomerase inhibitors, anti-angiogenesis agents and immunotherapy. Our understanding of ependymomas, which are rare tumours of the central nervous system, has increased substantially over the past 10 years. This Review discusses important biological features of ependymoma as well as key oncogenes, tumour suppressors and epigenetic changes that could potentially be exploited to improve therapy.

Automated summary

This review discusses important biological features of ependymomas, including subgroup categorization and clinical implications, oncogenic and tumor suppressor signaling pathways, epigenetic dysregulation, as well as the limitations of current therapies and potential next-generation treatments.